Home / Therapies / SGLT-2 Therapy Center (page 8)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

SGLT-2 Side Effects

Which is not a side effect of SGLT-2 Inhibitors?

A. Kidney failure
B. Hyperkalemia
C. Ketoacidosis
D. Hypertension
E. Increased cholesterol levels
F. Serious urinary tract infections
G. Increased bladder cancer risk
H. Serious allergic reactions

Follow the link for the answer.

Read More »

SGLT2 Inhibitors: A New Class of Diabetes Medications


What is a SGLT2 Inhibitor? Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also called gliflozin drugs,  are a new class of diabetic medications indicated for the treatment of type 2 diabetes. They have also been found to show cardiac benefits in patients with diabetes, and are being studied for possible use in type 1 diabetes. They work by reducing the absorption of glucose via the kidneys so that excess glucose is excreted through urination.

Read More »